Career history of Mann Muhsin
Former positions of Mann Muhsin
| Companies | Position | Start | End |
|---|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Chief Tech/Sci/R&D Officer | 2021-05-11 | 2022-01-16 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2019-03-31 | 2020-03-31 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 2016-02-29 | 2019-02-28 |
Training of Mann Muhsin
| University of Baghdad | Doctorate Degree |
Statistics
International
| United States | 3 |
| Canada | 2 |
| Iraq | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Mann Muhsin
- Experience
